Company research / ENDV
Endonovo Therapeutics, Inc. (ENDV)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
For the year ended 2022-12-31, Endonovo Therapeutics, Inc. reported revenue of $135.4K. Revenue grew 85.2% from the prior annual period.
Key ratios (year ended 2022-12-31)
92.6%
Gross margin
n/m
Operating margin
n/m
Net margin
85.2%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.